Belite Bio Files Marketing Authorization Application In Singapore, U.K., Switzerland For Tinlarebant To Treat Stargardt Disease Type 1

Belite Bio, Inc. (NASDAQ: BLTE) has submitted Marketing Authorization Applications for its investigational drug tinlarebant to treat Stargardt disease type 1 to regulatory authorities in Singapore, the United Kingdom, and Switzerland. Tinlarebant is a once-daily oral therapy targeting a rare retinal disease with no approved treatments currently available in these regions. The company focuses on developing therapeutics for degenerative retinal diseases with significant unmet medical needs.